| Literature DB >> 32655734 |
Srikrishna Varun Malayala1, Ambreen Raza2.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) has been associated with an increased risk of coronary artery disease (CAD) in women. HIV-positive pre-menopausal women lose the cardio-protective effect of estrogen and are at a higher risk for developing CAD. Our study intended to assess the cardiovascular risk in HIV-positive pre-menopausal women.Entities:
Keywords: HIV; Heart disease; Primary prevention; Women’s health
Year: 2020 PMID: 32655734 PMCID: PMC7331865 DOI: 10.14740/jocmr4226
Source DB: PubMed Journal: J Clin Med Res ISSN: 1918-3003
Framingham Coronary Artery Disease Risk Calculator [11]
| Variables | Response |
|---|---|
| Age | __ years |
| Gender | Male/female |
| Total cholesterol | __ mmol/L |
| HDL cholesterol | __ mmol/L |
| Smoker | Yes/no |
| Diabetes mellitus | Yes/no |
| Systolic blood pressure | __mm Hg |
| Is the person taking medicines for high blood pressure? | Yes/no |
HDL: high-density lipoprotein.
Figure 1Flow chart illustrating derivation of final sample. The total sample was 82,091. All the exclusion criteria were applied. The final sample was 9,639. Overall, 9,610 people were HIV-negative, four were HIV-indeterminate and 25 were HIV-positive. HIV: human immunodeficiency virus; MI: myocardial infarction.
Baseline Characteristics of the Sample
| Characteristics | HIV-positive women (N = 25) | HIV-negative women (N = 9,610) | P value |
|---|---|---|---|
| Age in years, mean (SD) | 39.44 (7.46) | 33.90 (8.94) | 0.147 |
| Race, n (%) | < 0.001 | ||
| Caucasian | 1 (4.0) | 4,030 (41.9) | |
| African American | 21 (84.0) | 1,916 (19.9) | |
| Hispanic | 2 (8.0) | 2,844 (29.6) | |
| Others | 1 (4.0) | 820 (8.5) | |
| Married, n (%) | 6 (24.0) | 4,802 (50) | 0.049 |
| Pregnant, n (%) | 1 (4.0) | 1,173 (12.2) | 0.358 |
| Family history of CAD, n (%) | 3 (12.0) | 1,199 (12.5) | 0.943 |
| Current smokers, n (%) | 0 (0.0) | 858 (8.9) | 0.242 |
| Diabetes mellitus, n (%) | 1 (4) | 537 (5.6) | 0.729 |
SD: standard deviation; CAD: coronary artery disease; HIV: human immunodeficiency virus.
Comparison of Framingham Risk Score and Its Component Variables Between HIV-Positive and HIV-Negative Pre-Menopausal Women
| Variables | HIV-positive pre-menopausal women (N = 25) | HIV-negative pre-menopausal women (N = 9,610) | P value |
|---|---|---|---|
| Age in years, mean (SD) | 39.44 (7.46) | 33.90 (8.94) | 0.147 |
| Systolic BP, mm Hg, mean (SD) | 113.4 (23.1) | 109.3 (18.6) | 0.215 |
| Diastolic BP*, mm Hg, mean (SD) | 67.23 (17.3) | 66.0 (13.8) | 0.136 |
| On medicines for BP, n (%) | 5 (20.0) | 930 (9.7) | 0.082 |
| Current smokers, n (%) | 0 (0.0) | 858 (8.9) | 0.242 |
| Hemoglobin A1c, mean (SD) | 5.27 (0.42) | 5.33 (0.79) | 0.531 |
| HDL cholesterol, mg/dL, mean (SD) | 45.4 (9.8) | 57.4 (16.2) | 0.050 |
| Total cholesterol, mg/dL, mean (SD) | 187.0 (42.5) | 192.5 (41.4) | 0.523 |
| C-reactive protein*, mg/dL, mean (SD) | 0.36 (0.31) | 0.51 (0.82) | 0.113 |
| Framingham 10-year risk score | 2.12 (2.73) | 0.95 (1.93) | 0.010 |
*Diastolic blood pressure and C-reactive protein are not part of the Framingham risk score. SD: standard deviation; BP: blood pressure; HDL: high-density lipoprotein; HIV: human immunodeficiency virus.
Comparison of Cardiovascular Risk Factor Modification Strategies Between HIV-Positive and HIV-Negative Pre-Menopausal Women
| HIV-positive pre-menopausal women (N = 25) | HIV-negative pre-menopausal women (N = 9,610) | P value | |
|---|---|---|---|
| Physician’s advices on lifestyle modification | |||
| Told to lose weight, n (%) | 4 (16.0) | 1,020 (10.6) | 0.383 |
| Told to exercise, n (%) | 7 (28.0) | 1,254 (13.0) | 0.027 |
| Told to modify diet, n (%) | 7 (28.0) | 1,277 (13.3) | 0.031 |
| Patient’s adherence to lifestyle modification | |||
| Trying to lose weight, n (%) | 7 (28.0) | 1,864 (19.0) | 0.277 |
| Trying to increase exercise, n (%) | 6 (24.0) | 1,821 (18.9) | 0.520 |
| Trying to modify diet, n (%) | 8 (32.0) | 2,356 (24.5) | 0.385 |
| Tried to quit smoking, n (%) | 0 (0.0) | 163 (1.7) | 0.485 |
HIV: human immunodeficiency virus.